Reporter brief
Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis
What happened
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This describes a trial design rather than reported results; efficacy of senolytics in MS cannot be determined from this abstract alone. The study was designed to assess safety and feasibility, not to establish clinical benefit. No sample size, effect sizes, or outcome data are reported.
Study design and sample
Rct; Human.
Adults with secondary progressive multiple sclerosis (SPMS), aged 50-85 years, not currently taking MS disease-modifying therapy, with worsening MS symptoms
- Design
- Rct
- Sample
- —
- Journal
- Ohio State University
- Published
- Dec 8, 2025
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.